-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CLsGm+QUAKBv/iLyzHCtN0fkH2QIxE7dFf92+a8vdlNWQaAMZLAspRsci44CD/K8 rlmPl/4PPrjXDxYREm+65g== 0001193125-09-016277.txt : 20090202 0001193125-09-016277.hdr.sgml : 20090202 20090202145550 ACCESSION NUMBER: 0001193125-09-016277 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090202 DATE AS OF CHANGE: 20090202 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BRIGHAM MICHAEL F CENTRAL INDEX KEY: 0001136544 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: BUSINESS PHONE: 2078782770 MAIL ADDRESS: STREET 1: IMMUCELL CORP STREET 2: 56 EVERGREEN DRIVE CITY: PORTLAND STATE: ME ZIP: 04103 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IMMUCELL CORP /DE/ CENTRAL INDEX KEY: 0000811641 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 010382980 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-39373 FILM NUMBER: 09561119 BUSINESS ADDRESS: STREET 1: 56 EVERGREEN DR CITY: PORTLAND STATE: ME ZIP: 04103 BUSINESS PHONE: 2078782770 MAIL ADDRESS: STREET 1: 56 EVERGREEN DRIVE CITY: PORTLAND STATE: ME ZIP: 04103 SC 13D 1 dsc13d.htm SCHEDULE 13D Schedule 13D

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

(Amendment No.             )*

 

 

 

ImmuCell Corporation

(Name of Issuer)

 

 

Common Stock, par value $0.10 per share

(Title of Class of Securities)

 

 

452525306

(CUSIP Number)

 

 

Michael F. Brigham, President and CEO

ImmuCell Corporation

56 Evergreen Drive

Portland, ME 04103

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

 

February 2, 2009

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box.  x

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No 452525306    Page 2 of 4

 

  (1)  

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only).

 

            Michael F. Brigham

    
  (2)  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ¨

(b)  ¨

    
  (3)  

SEC Use Only

 

    
  (4)  

Source of Funds (See Instructions)

 

            P F

    
  (5)  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

   ¨
  (6)  

Citizenship or Place of Organization

 

            USA

    

Number of  

Shares  

Beneficially  

Owned by  

Each  

Reporting  

Person  

With  

  

  (7)    Sole Voting Power

 

                202,870

 

  (8)    Shared Voting Power

 

                n/a

 

  (9)    Sole Dispositive Power

 

                202,870

 

(10)    Shared Dispositive Power

 

                n/a

(11)  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

            202,870

    
(12)  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

   ¨
(13)  

Percent of Class Represented by Amount in Row (11)

 

            6.8%

    
(14)  

Type of Reporting Person (See Instructions)

 

            I N

    

 

Item 1. Security and Issuer.

Common stock, par value $0.10 per share

ImmuCell Corporation

56 Evergreen Drive

Portland, ME 04103

 

Item 2. Identity and Background.

a) Michael F. Brigham

b) c/o ImmuCell Corporation

56 Evergreen Drive

Portland, ME 04103

c) President and CEO of ImmuCell Corporation

d) This person has not been convicted in a criminal proceeding during the last five years

e) This person was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction during the last five years.

f) USA

 

Item 3. Source and Amount of Funds or Other Consideration.

The source of the $152,708 used to acquire the common stock is personal funds of the reporting person.

 

Item 4. Purpose of Transaction.

The purpose of the acquisition is personal investment.

 

Item 5. Interest in Securities of the Issuer.

The 202,870 shares, which represents 6.8% of the outstanding common stock, include 100,000 shares subject to stock options that are currently exercisable.

 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

n/a

 

Item 7. Material to be Filed as Exhibits.

n/a

This Schedule 13D is filed in lieu of and replaces previously filed Schedule 13G’s.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true and correct.

Dated as of February 2, 2009

 

 

/s/ Michael F. Brigham

Name:   Michael F. Brigham
Title:   President and CEO
 -----END PRIVACY-ENHANCED MESSAGE-----